GlassScriptPhysician profile
Gabriel L Mosier
NPI 1407276611
$3,703.12
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $706 · 2021: $1,736 · 2022: $1,261.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.69 | 2020-2022 | |
| Lilly USA, LLC | $349.65 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $331.84 | 2020-2022 | |
| Novo Nordisk INC | $302.46 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $260.11 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $212.87 | 2020-2022 | |
| Pfizer INC. | $182.97 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.71 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.09 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.79 | 2022 | |
| Amgen INC. | $113.20 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $93.17 | 2021-2022 | |
| Dexcom, INC. | $81.31 | 2021-2022 | |
| Allergan, INC. | $79.74 | 2020 | |
| Glaxosmithkline, LLC. | $79.57 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $77.21 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.47 | 2020-2021 | |
| Abbott Laboratories | $68.60 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $50.82 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $45.51 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $44.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $43.39 | 2021 | |
| Daiichi Sankyo INC. | $40.15 | 2020-2022 | |
| Amarin Pharma, INC. | $34.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.91 | 2022 | |
| Astellas Pharma US INC | $24.57 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.73 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $19.24 | 2022 | |
| Biogen, INC. | $16.41 | 2021 | |
| Eisai INC. | $16.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.55 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Mosier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.